📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries. (2023)

First Author: Elshatlawy M

Attributed to: Understanding and targeting oncogenic biomolecular condensates of ALK kinase funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/1878-0261.13446

PubMed Identifier: 37149843

Publication URI: http://europepmc.org/abstract/MED/37149843

Type: Journal Article/Review

Volume: 17

Parent Publication: Molecular oncology

Issue: 6

ISSN: 1574-7891